Ariel Rechtman

Mr. Ariel Rechtman

Hebrew University of Jerusalem, Jerusalem, Southern, Israel
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
LBLivnat Brill
Livnat Brill
ARAriel Rechtman
Ariel Rechtman
OZOmri Zveik
Omri Zveik
NHNitzan Haham
Nitzan Haham
EOEsther Oiknine-Djian
Esther Oiknine-Djian
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky
The SARS-CoV-2 pandemic has presented a clinical concern for patients with multiple sclerosis (MS), whose mainstay treatment are immunosuppressive/immunomodulatory disease-modifying therapies.1 Most approved vaccines, including the messenger RNA vaccines, induce robust humoral and cellular immune responses against the virus spike protein2,3; however, it is still unknown whether SARS-CoV-2 vaccines confer sufficient protection in patients with MS treated with disease-modifying therapies.

23 October 2021 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
LBLivnat Brill
Livnat Brill
ARAriel Rechtman
Ariel Rechtman
OZOmri Zveik
Omri Zveik
NHNitzan Haham
Nitzan Haham
NLNetta Levin
Netta Levin
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky

10 May 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
LBLivnat Brill
Livnat Brill
ARAriel Rechtman
Ariel Rechtman
ASAlla Shifrin
Alla Shifrin
ARAyal Rozenberg
Ayal Rozenberg
SASvetlana Afanasiev
Svetlana Afanasiev
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky

Verified
Journal Article
Open access
PDF file
OZOmri Zveik
Omri Zveik
ARAriel Rechtman
Ariel Rechtman
NHNitzan Haham
Nitzan Haham
IAIrit Adini
Irit Adini
TCTamar Canello
Tamar Canello
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky
Neuromyelitis optica (NMO) is a rare disease usually presenting with bilateral or unilateral optic neuritis with simultaneous or sequential transverse myelitis. Autoantibodies directed against aquaporin-4 (AQP4-IgG) are found in most patients. They are believed to cross the blood–brain barrier, target astrocytes, activate complement, and eventually lead to astrocyte destruction, demyelination, and axonal damage. However, it is still not clear what the primary pathological event is. We hypothesize that the interaction of AQP4-IgG and astrocytes leads to DNA damage and apoptosis. We studied the effect of sera from seropositive NMO patients and healthy controls (HCs) on astrocytes’ immune gene expression and viability. We found that sera from seropositive NMO patients led to higher expression of apoptosis-related genes, including BH3-interacting domain death agonist (BID), which is the most significant differentiating gene (p < 0.0001), and triggered more apoptosis in astrocytes compared to sera from HCs. Furthermore, NMO sera increased DNA damage and led to a higher expression of immunological genes that interact with BID (TLR4 and NOD-1). Our findings suggest that sera of seropositive NMO patients might cause astrocytic DNA damage and apoptosis. It may be one of the mechanisms implicated in the primary pathological event in NMO and provide new avenues for therapeutic intervention.

2 December 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
ARAriel Rechtman
Ariel Rechtman
OZOmri Zveik
Omri Zveik
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky
Background: Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are demyelinating diseases of the central nervous system. Brain atrophy is well recognized in multiple sclerosis; however, approximately 50% of studies report no significant difference in overall brain volumes when comparing NMOSD patients with healthy controls (HCs). To quantitatively assess differences in brain volume and white matter integrity in NMOSD and MOGAD patients compared to HCs through a meta-analysis. Methods: A systematic literature search of English articles in PubMed was performed through December 2024. We analyzed sixty-one studies that met the inclusion criteria, providing volumetric MRI or diffusion tensor imaging data with HC comparisons. Outcomes of interest included brain volume, and DTI parameters. Standardized mean differences were computed, and random-effects meta-analyses were performed to account for study heterogeneity. Results: The studies included data from 1,786 NMOSD patients, 376 MOGAD patients, and 1,936 HCs. NMOSD patients exhibited significantly lower total brain, gray, and white matter volumes compared to HCs. Notable atrophy was observed in several regions including the accumbens, brainstem, caudate, cerebellum, hippocampus, putamen, and thalamus. MOGAD patients have reduced brain volume compared to HCs. Furthermore, comparisons demonstrated that NMOSD patients had significantly lower brain and gray matter volumes than MOGAD patients. Conclusion: Our meta-analysis confirms substantial brain atrophy in NMOSD patients compared to both HCs and individuals with MOGAD, indicating a more pronounced neurodegenerative impact than previously recognized. These findings carry important clinical implications by enhancing our understanding of disease-specific imaging biomarkers.

12 August 2025 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
TFTal Friedman-Korn
Tal Friedman-Korn
ARAriel Rechtman
Ariel Rechtman
OZOmri Zveik
Omri Zveik
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky